🇺🇸·5h agoIndustry
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
Publisher
E
Eli Lilly News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investor.lilly.com
Leave the platform to read the original full article on the publisher site.
Source: Eli Lilly News
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News·5h ago
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Roche Newsroom·11h ago
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
Ipsen RSS·11h ago
The role of biomarkers: how new modalities are making precision medicine a reality
GSK News·1d ago